The eosinophilic esophagitis market is estimated to be valued at USD 237.5 Mn in 2024 growing at a CAGR of 33.2% over the forecast period (2024 – 2031). The market is witnessing high growth owing to rising prevalence of Eosinophilic Esophagitis (EoE) across the globe and increasing diagnosis rate of the disease. Furthermore, rising research and development activities for development of new treatment options are augmenting market growth.
Market Dynamics:
Growth in the global eosinophilic esophagitis market is driven by the rising prevalence of the disease owing to changing dietary habits and environmental pollution. The increased awareness regarding symptoms of EoE and development of improved diagnostic methods have led to improved diagnosis rate contributing to market growth. Furthermore, strong pipeline with several pharmaceutical companies conducting clinical trials for developing effective drugs for EoE treatment will boost the market over the forecast period. Introduction of oral corticosteroids as primary treatment option is also supporting market growth.
Increasing Prevalence of Allergies is Driving Growth in the Eosinophilic Esophagitis Market
One of the major drivers for the growth of the eosinophilic esophagitis market is the rising prevalence of allergies globally. Eosinophilic Esophagitis (EoE) is an immune/allergy-driven disease where there is an infiltration of eosinophils in the esophagus. Some of the major food allergies linked to EoE include dairy, eggs, wheat, soy, and nuts. With changing lifestyle and food habits, the incidence of various allergies has seen a sharp rise over the past few decades. According to studies, over 50 million Americans currently suffer from some form of food allergy. This growing allergy epidemic is directly fueling the increase in EoE cases. As such, pharmaceutical companies are developing novel allergy therapies and drugs targeting eosinophils to tap into this lucrative patient population.
Increasing Adoption of Biologics for EoE Treatment Augmenting Market Growth
Biologics targeting interleukin-5 (IL-5) and immunoglobulin E (IgE) pathways have shown promising results for the treatment of severe and refractory EoE. Drugs like Dupixent (dupilumab) and Fasenra (benralizumab) that block IL-5 actions are gaining wider acceptance from both physicians as well as patients. In addition, pharmaceutical giants are investing heavily in developing IL-13 inhibitors which also hold potential in modulating pathogenic pathways in EoE. The approval and commercialization of such cutting-edge biologics are enhancing the treatment landscape and driving higher spending on novel EoE therapies. As biologics emerge as the treatment of choice for difficult-to-manage EoE cases, their rising demand will serve as a key growth driver for this market.
Lack of Disease Awareness Hampering Diagnosis Rates
One of the major restraints affecting the eosinophilic esophagitis market expansion is the low disease awareness among both patients and healthcare providers. Since the symptoms of EoE like dysphagia and food impaction are rarely specific, the condition often goes undiagnosed for a long time. Many patients suffering from EoE fail to connect their symptoms to the disease and end up seeing multiple physicians before arriving at an accurate diagnosis. Moreover, primary care doctors and gastroenterologists also lack comprehensive knowledge about key diagnostic techniques and pathophysiology of EoE. This lack of awareness leads to underdiagnosis and late-stage diagnosis, limiting the patient pool accessing correct and timely treatments. Targeted awareness campaigns and education programs can help address this important market barrier.
Stringent Regulatory Approval Process Delaying New Product Launches
Another significant challenge faced by companies operating in this market is the rigorous and lengthy drug approval process. Since EoE is a rare disease with an unclear pathomechanism and diagnostic criteria, regulators demand extensive clinical data to approve new therapies. Sponsors must invest heavily in conducting well-designed multicenter trials over several years to generate robust safety and efficacy endpoints. This prolonged approval timeline has discouraged some key product launches. Furthermore, considering the orphan drug designation criteria is complex with evolving guidelines, approval for such niche areas take further time. Streamlining the regulatory pathways while maintaining scientific rigor can help spur product innovation and introduce more cost-effective options in the market.
Rising Focus on Biomarker Development Opening New Avenues
One of the major opportunities in the eosinophilic esophagitis market is the increasing research into novel disease biomarkers. While eosinophil counts in biopsy samples serve as the standard diagnostic marker currently, developing blood-based, imaging, and molecular biomarkers hold potential to transform disease management. Non-invasive tests can help early diagnosis, aid therapeutic monitoring, and enable objective assessment of treatment response over time. Several studies are investigating markers like serum eotaxin-3 levels, cytokine profiles, and genetic signatures associated with EoE pathogenesis. Commercialization of reliable biomarkers can enable widespread screening, improve diagnosis rates, facilitate remote monitoring and present financially lucrative prospects for market players.
Growing Research on Alternative Treatment Modalities Attracting Investments
Another key opportunity lies in exploring alternative treatment modalities beyond conventional drugs. Novel interventional endoscopic approaches are gaining focus for managing EoE complications and localized therapies. Research into modified diets, use of probiotics supplements, role of vitamins/minerals are providing insights for adjunct management strategies. Besides, repurposing existing drugs holds promise.
Link - https://www.coherentmarketinsights.com/market-insight/eosinophilic-esophagitis-market-4909
Key Development
- On February 12, 2024, Takeda Pharmaceutical Company Limited, a multinational pharmaceutical company, announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Eohilia (budesonide oral suspension) for the treatment of eosinophilic esophagitis (EoE) in patients aged 11 and older. The regulatory action makes Eohilia the first and only approved oral drug for this patient population, and Takeda Pharmaceutical Company Limited expects Eohilia 2 mg/10 mL single-dose stick packs to be ready by the end of February 2024.
- On January 30, 2024, Revolo Biotherapeutics, a leading biotechnology firm, disclosed that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to '1104, a groundbreaking immune-resetting peptide under investigation as a potential treatment for eosinophilic esophagitis. Revolo Biotherapeutics submitted its initial request prior to the commencement of its Phase 2a EoE trial (RVLO 121-04) and subsequently revised it in light of the favorable outcomes from an additional Phase 2 study.
- On January 25, 2024, Regeneron Pharmaceuticals, Inc., a renowned biotechnology company, and Sanofi, a distinguished pharmaceutical and healthcare enterprise, jointly announced that the U.S. Food and Drug Administration (FDA) has granted approval to Dupixent (dupilumab) for the treatment of eosinophilic esophagitis (EoE) in pediatric patients aged 1 to 11 years with a minimum weight of 15 kg. This approval establishes Dupixent as the inaugural and sole medication sanctioned in the U.S. specifically for addressing the needs of this patient population.
- On January 8, 2024, Calypso Biotech BV, a leader in Interleukin-15 (IL-15) targeted therapy development, disclosed an acquisition agreement with Novartis AG, a prominent pharmaceutical company. With this acquisition, Novartis AG gained full ownership of CALY-002. Novartis AG intends to expand its exploration of CALY-002 across various autoimmune diseases characterized by substantial unmet medical requirements. CALY-002 is currently undergoing evaluation in a Phase 1b trial involving patients afflicted with Celiac Disease and Eosinophilic Esophagitis.
Key Players: Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
